Referenced for the GLP-1 / triple-agonist market-size projection
Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)
IR/IGF-1 receptor hybrids and IR-A lead to an over-activation of the IGF pathway, causing an enhanced mitogenic signaling and cancer development (Malaguarnera et al., 2011)
A missed dose may: Disrupt the hormonal balance your body was adapting to Delay or alter your menstrual cycle May worsen cycle issues after weight loss or low calorie intake Its also worth noting that some women experience temporary cycle changes just from being on GLP-1 therapy, even if they havent missed a dose
Normally, when calories are reduced, the body adapts by lowering metabolism
Understanding the Key Players First, lets briefly review the two active ingredients in this specialized compound